Validation of Hepascore as a Predictor of Liver Fibrosis in Patients with Chronic Hepatitis C Infection

Abstract EN

Introduction.

Liver biopsy is an invasive determinator for hepatic fibrosis.

Serum biomarkers can probably be used as an alternative to liver biopsy in assessment of the degree of fibrosis in patients with chronic Hepatitis C.

Method.

Eighty patients with chronic Hepatitis C were included in the study using simple nonrandom sampeling metod.

After fulfillment of liver biopsy, the patients were categorized according to the METAVIR Scoring system.

The Hepascore algorithm is computed based on age, sex, and the serum levels of total bilirubin, δ-glutamyl transferase, α2-Macroglobulin, and hyaluronic acid.

The spearman and ROC tests were used.

Results.

According to the liver biopsy results, 12, 25, 20, 7 and 16 patients had F0, F1, F2, F3, and F4, respectively.

With regard to the 0.34 cut-off point Hepascore had 67%, 56%, 64%, and 56% sensitivity, specificity, respectively, positive prediction value (PPV), and negative prediction value (NPV), respectively, for diagnosis of significant fibrosis.

For a Hepascore cut-off point 0.61, sensitivity, specificity, respectively, PPV and NPB 82%, 86%, 70%, and 92% in diagnosis of severe fibrosis.

For a Hepascore cut-off point 0.84, sensitivity, specificity, PPV and NPB were respectively 100%, 97%, 89%, and 100% for diagnosis of cirrhosis.

Conclusion.

Hepascore has a high value in diagnosis of the level of fibrosis, particularly cirrhosis.

Therefore, it can be used for primary screening of patients to determine the need for liver biopsy.